Evidence map›Paper›PMID 42259988›Full record

Trial reportNature cancer2026

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial.

Peter Schmid, Seock-Ah Im, Zbigniew Nowecki, Piotr J Wysocki, Jacek Jassem, Kyung Hae Jung, Simon Lord, Jon Armstrong, Ross Stewart, Petra Vuković and 2 more

Abstract readMulticenter StudyClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Peter SchmidBarts Cancer Institute, Queen Mary University of London, London, UK. p.schmid@qmul.ac.uk.ORCID http://orcid.org/0000-0001-9817-5228
Seock-Ah ImSeoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0002-5396-6533
Zbigniew NoweckiMaria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Piotr J WysockiDepartment of Oncology, Jagiellonian University - Medical College, Krakow, Poland.ORCID http://orcid.org/0000-0003-4003-5278
Jacek JassemMedical University of Gdańsk, Gdańsk, Poland.ORCID http://orcid.org/0000-0002-8875-6747
Kyung Hae JungAsan Medical Center, University of Ulsan, College of Medicine, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0002-1580-7224
Simon LordMedical Sciences Division, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-7946-5609
Jon ArmstrongAstraZeneca, Cambridge, UK.
Ross StewartAstraZeneca, Cambridge, UK.
Petra VukovićAstraZeneca, Cambridge, UK.
Neelima DenduluriAstraZeneca, Gaithersburg, MD, USA.
Yeon Hee ParkSamsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

More effective therapies are required for advanced breast cancer. We report results from 58 women with locally advanced unresectable or metastatic hormone-receptor (HR)-negative, human epidermal growth factor receptor 2 (HER2)-low breast cancer enrolled in arm 6 of the multicenter, open-label phase 1b/2 BEGONIA platform trial, who received durvalumab (1,120 mg) plus trastuzumab deruxtecan (T-DXd; 5.4 mg kg

Indexed as

Antibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesTrastuzumabAdultAgedCamptothecinFemaleHumansImmunoconjugatesMiddle AgedNeoplasm MetastasisReceptors, EstrogenReceptors, ProgesteroneAntibodies, MonoclonalCamptothecindurvalumabERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoconjugatesReceptors, EstrogenReceptors, ProgesteroneTrastuzumabtrastuzumab deruxtecan

Identifiers

PMID42259988
PMCPMC13309285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.